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RFABackground: Long-term survival can be obtained with local treatment of lung metastases from colorectal
cancer. However, it is unclear as to what the optimal local therapy is: surgery, radiofrequency ablation
(RFA) or stereotactic radiotherapy (SBRT).
Methods: A systematic review included 27 studies matching with the a priori selection criteria, the most
important being P50 patients and a follow-up period of P24 months. No SBRT studies were eligible. The
review was therefore conducted on 4 RFA and 23 surgical series.
Results: Four of the surgical studies were prospective, all others were retrospective. No randomized trial
was found. The reporting of data differed between the studies, which led to difficulties in the analyses.
Treatment-related mortality rates for RFA and surgery were 0% and 1.4–2.4%, respectively, whereas mor-
bidity rates were reported inconsistently but seemed the lowest for surgery.
Conclusion: Due to the lack of phase III trials, no firm conclusions can be drawn, although most evidence
supports surgery as the most effective treatment option. High-quality trials comparing currently used
treatment modalities such as SBRT, RFA and surgery are needed to inform treatment decisions.
 2013 Elsevier Ltd. All rights reserved.Introduction
Colorectal cancer is the third most common tumor type in
males, and the second in females, with in 2008 an incidence of
1.2 million new cases and a mortality rate of over 600.000
world-wide.1 In the Netherlands, approximately 20% of colorectal
cancer patients have synchronic metastatic disease at time of
diagnosis.2
Although the cure rate of patients with colorectal cancer has
improved over the last decades, distant metastases are still of con-
cern. Temporary remissions with systemic treatment can be ob-
tained, but most of the time, cure remains elusive once distantmetastases have occurred. In 1995, Hellman and colleagues pro-
posed an intermediate state between localized cancer and distant
metastases, called ‘‘oligo-metastases’’.3 In this concept, treatment
of a few distant metastases with curative intent may still be possi-
ble, if all visible cancer can be eradicated with local treatments
such as radiotherapy, surgery or radiofrequency ablation (RFA).
The observation that long-term survival may be achieved with
surgical resection of liver metastases from colorectal cancer4 has
been used as an argument supporting the oligo-metastases con-
cept. Besides liver, also lung metastases from colorectal cancer
have been treated with curative or radical intent. Most series deal
with surgery, although RFA and Stereotactic Body Radiation Ther-
apy or SBRT5 (also called SABR, Stereotactic Ablative RadioTherapy)
are used as well. Most studies included patients with several types
of primary tumors, whilst few studies reported outcomes on lung
metastases from primary colorectal cancer, only. To the best of
our knowledge, most series are retrospective or observational
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treatment modalities have been published. This was the reason
for Treasure et al.6 to perform an ongoing phase III trial that inves-
tigates whether or not pulmonary metastasectomy in colorectal
cancer influences survival.
Several systematic reviews regarding one or more of the three
local treatment methods have been published.7–9 However, to the
best of our knowledge, no systematic review has been reported
comparing the outcome of surgery, RFA and SBRT specifically in
the treatment of lung metastases of colorectal cancer. This was
the aim of the current review.
Methods
Search strategy and selection criteria
The literature search was performed by using a broad strategy
which was composed by following the PICO method10,11 (Supple-
mentary Material 1). The complete search strategy is shown in
Appendix 1 and was used to identify studies in Pub Med, EMBASE,
Web of Science and the Cochrane Library from 2001 until the
search date in October 2011.
For this review a priori selection criteria were established prior
to the search and selection of articles. These included a minimal
follow-up period of 24 months, a minimum of 50 patients included
in the study with pulmonary metastases from colorectal cancer
without constraint on previous therapies. Only original articles
were included. Another limitation used was language, in which
only English, German and Dutch articles were included. All inclu-
sion- and exclusion criteria are summarized in Table 1.
In order to complete the search and to identify all relevant stud-
ies, the references of all eligible articles were manually searched
for other potentially relevant studies.
Outcomes
One researcher conducted the search and selection of eligible
studies. All articles were then evaluated by two independent
reviewers. When available, the following data were obtained from
the trials: patient and tumor characteristics, inclusion- and exclu-
sion criteria, disease-free interval, treatment technique, follow-up,
complications, tumor progression, recurrence rate, survival and
prognostic factors.
One researcher (R.S.) reviewed all eligible studies, whereas the
second extraction was performed by three reviewers (R.H., J.G.
and D.D.R.). Data were extracted and tabulated independently in
order to reach validity of the data (appendix 2 for extraction table).
If outcomes differed, there was discussion between the reviewers
until consensus was reached.
Results
Search results
The initial search in the four databases included 4727 articles in
total, which were searched for duplicates using Endnote by which
453 duplicates were excluded.Table 1
Inclusion and exclusion criteria for the literature search.
Follow-up period P24 months
Site of primary tumor Colorectal carcinoma
Number of patients Pn = 50
Previous treatment All therapies
Tumor stage Stage IV
Type of metastasis Recurrence or first secondary tumor
Study type Reviews excludedThe remaining studies were manually evaluated and 226 more
duplicates were excluded. Another 3250 studies were then ex-
cluded based on titles that were not relevant for this study
(Fig. 1) leaving a total of 798 studies for further analysis.
Abstracts of all remaining 798 studies were then compared to
the a priori selection criteria. Studies not matching these criteria
were excluded as well. After this first selection, 27 relevant studies
were identified and included in this review. Of these 27, the major-
ity (23) focused on surgery, four examined RFA and none regarded
SBRT.
Description of the studies
Of the twenty-seven studies that matched the selection criteria
and were included in this review, four studies investigated RFA, all
of which were retrospective.12–15 Three of these studies were per-
formed in the same institute in Sydney, Australia13–15 with two of
these papers13,14 investigating the same patient population. In our
analysis, we used this population only once. All twenty-three
remaining studies reviewed surgical metastasectomy, of which
four prospective studies and the remaining retrospective studies.
Study and patient characteristics are found in Table 2.
Despite the known importance according to the ‘‘oligo-metasta-
ses hypothesis’’,3 only six studies reported on the median or mean
number of the pulmonary lesions. Yan et al.13,14 reported a median
of 2 lesions per patient (range, 1–6), whilst Kanemitsu et al.16 and
Pfannschmidt et al.17 found a median of 1 lesion per patient
(ranges, 1–8 and 1–35 lesions, respectively). Two series only re-
ported mean values of 2.3 ± 2.1 lesions18 and 1.6 ± 0.8 lesions.19
Other study and patient characteristics such as tumor diameter
and follow-up durations are listed in Table 2.Fig. 1. Flowchart of selection process.
Table 2
Patient characteristics.
Study Patient sex/age No. of tumors Involved lobes Tumor diameter Follow-up
Yamakado (2009); RFA, CT guided;
(Retrospective, n = 78); Mie,
Japan
Sex: M/F: 53/25; mean age
66.1 ± 9.8y (range, 40–87 year);
665 year: n = 29; >65 year: n = 49
1 lesion: n = 34; P2 lesions: n = 44 Unilateral n = 49; Bilateral n = 29 Mean max size: 2.0 ± 1.0 cm (range
0.6–6.0 cm); TD 6 3 cm n = 70;
TD > 3 cm n = 8
Mean 24.6 months ± 17.6 months
(range, 6.0–84.1 months)
Yan (2006); RFA, CT guided;
(Retrospective, n = 55); Sydney,
Australia
Sex: M/F: 33/22; mean age
62 ± 11 year; 665 year: n = 29;
>65 year: n = 26
1–2 lesions: n = 39; 3–6 lesions:
n = 16; mean pp 2 lesions ± 2;
median pp 2 lesions (range, 1–6)
1 lobe: n = 39, 2–4 lobes n = 16 Mean max size: 2.1 ± 1.1 cm;
TD 6 3 n = 42; TD > 3 cm n = 13
Median 24 months (range, 6–
40 months): complete FU
Yan (2007); RFA, CT guided;
(Retrospective, n = 55); Sydney,
Australia
Sex: M/F: 33/22; mean age
62 ± 11 year; 665 year: n = 29;
>65 year: n = 26
1–2 lesions: n = 39; 3–6 lesions:
n = 16; mean pp 2 lesions ± 2;
median pp 2 lesions (range, 1–6)
1 lobe: n = 39, 2–4 lobes n = 16 Mean max size: 2.1 ± 1.1 cm;
TD 6 3 n = 42; TD > 3 cm n = 13
Median 24 months (range, 6–
40 months): complete FU
Chua (2010); RFA, CT guided;
(Retrospective, n = 108); Sydney,
Australia
Sex: M/F: 83/65; median age
63 year (range 30–85); 660 year:
n = 50; >60 year: n = 98
1–2 lesions: n = 104; P3 lesions:
n = 44
Unilateral n = 107; Bilateral n = 41 Mean max size: 2 ± 2 cm;
TD 6 4 cm n = 89; TD > 4 cm n = 59
Median 29 months (range, 2–
103 months)
Brouquet (2011); Surgery; (Retro- /
prospective, n = 112); Houston,
U.S.
Sex: M/F: 78/34; mean age
55 year ± 11 year
Mean pp 2.3 lesions ± 2.1 Unilateral n = 78; Bilateral n = 34 Mean size 1.5 cm ± 1.2 Median 49 months (range, 0.1–
159.0 months)
Koga (2006); Surgery;
(Retrospective, n = 58); Tokyo,
Japan
Sex: M/F: 30/28; median age
63 year (range, 33–87 year)
1 lesion n = 23; 2 lesions n = 16; 3
lesions n = 10; 4–12 lesions n = 9
Unilateral n = 45; Bilateral n = 13 TD 6 3 cm n = 31; TD > 3 cm n = 27 Median 24 months (range, 5–
233 months)
Ogata (2005); Surgery;
(Retrospective, n = 76); Fukuoka,
Japan
Sex: M/F: 39/37; mean age
62.9 year (range, 41–83 year)
1 lesion n = 56; 2 lesions n = 15; 3
lesions n = 4; 4 lesions n = 1
Unilateral n = 69; Bilateral n = 7 Mean size 2.69 ± 1.47 (range, 0.7–
10.0 cm); TD < 3 cm n = 29;
TD P 3 cm n = 47




Sex: M/F: 27/31; median age
62 year (range, 36–84 year)
Median 1 lesion (range, 1–8) Unilateral n = 45; Bilateral n = 13 Median max size 2.0 cm (range 1–
8 cm)
Median: 39 months (range, 5–
94 months) (total group); median
51 months (range, 29–89 months)
(surviving patients)
Park (2010); Surgery;
(Retrospective, n = 195); Seoul,
South Korea
Sex: M/F: 122/73; median age
58 year ± 9.5 year
1 lesion n = 112; 2–4 lesions I = 70;
>5 lesions n = 10; unknown n = 3
Unilateral n = 146; Bilateral n = 48 Max size:64 cm n = 170; >4 cm
n = 17; undocumented n = 8
Median 42.3 months; loss-to
follow-up n = 1
Headrick (2001); Surgery;
(Retrospective, n = 58);
Rochester, U.S.
Sex: M/F: 37/21; median age
59 year (range, 31–82 year)
1 lesions n = 31; 2 lesions n = 13; 3
lesions n = 10; 4 lesions n = 4
N/A N/A Median 62 months (range, 6–
201 months)
Hornbech (2011); Surgery;
(Retrospective, n = 53);
Copenhagen, Denmark
N/A Unilateral n = 41; Bilateral n = 12 N/A Mean for all tumor sites;
61.6 months. Only analysis with
patients with minimal FU of
36 months
Inoue (2004); Surgery;
(Retrospective, n = 128); Osaka,
Japan
Sex: M/F: 85/43; mean age
61.8 year (range, 39–78 year)
1 lesion n = 95; P2 lesions n = 33 N/A N/A Mean 85.9 months; loss-to follow-
up n = 7
Chen (2009); Surgery;
(Retrospective, n = 84); Kyoto,
Japan
Sex: M/F: 54/30; median age
65 year (range, 41–86 year)
1 lesion n = 22; 2–4 lesions n = 51;
P5 lesions n = 11
Unilateral n = 68; Bilateral n = 16 TD < 3 cm n = 18; TD P 3 cm n = 66 Median 28 months (range, 3–
135 months)
Hwang (2010); Surgery;
(Prospective, n = 125);
Gyeonggi-do, South Korea
Sex: M/F: 75/50; median age
60 year (range, 32–80 year); 660
n = 64; >60 n = 61
1 lesion n = 77; 63 lesions n = 109;
>3 lesions n = 16
Unilateral n = 94; Bilateral n = 31 Median size 1.8 cm (range, 0.5–
7.0 cm); TD 6 2 cm n = 85;
TD > 2 cm n = 40
Median 46 months (range, 21–
99 months)
Riquet (2010); Surgery;
(Retrospective, n = 117); Paris,
France
Sex: M/F: 74/53; median age
65 year (range, 36–85 year);
<65 year n = 62; >65 year n = 65
Total 314; 1 lesion n = 75; P2
lesions n = 42
N/A Median size 3.0 ± 1.9 cm (range,
0.2–9.0 cm); TD < 2.9 cm n = 64;
TD > 3.0 cm n = 53
Median 46 months (range, 2–
256 months)
Rama (2008); Surgery;
(Retrospective, n = 62); Lisbon,
Portugal
Sex: M/F: 42/19; mean age
61 year ± 14 year (range, 30–
80 year)
Mean 1.6 lesions ± 0.8; 1 lesion:
n = 37; 2 lesions n = 13; P3 lesions
n = 11
Unilateral n = 59; Bilateral n = 2 TD 6 3 cm n = 44; TD > 3 cm n = 17 Mean 39 months ± 39 months
(range, 4–173 months); complete
n = 56, n = 5 excluded from analysis
Takakura (2009); Surgery;
(Retrospective, n = 56);
Hiroshima, Japan
Sex: M/F: 26/30; median age
64 year (range 42–76 year)
1 lesion n = 37; P2 lesions n = 19
(range 2–14)
Unilateral n = 44; Bilateral n = 12 Median size 2 cm (range 0.5–
8.8 cm)
Mean 30 months
Lin (2009); Surgery; (Prospective,
n = 63); Taipei, Taiwan
Sex: M/F: 39/24; median age
58.7 year (range 32–
1 lesion n = 41; 2 lesions n = 14; 3
lesions n = 5; P4 lesions n = 3
Unilateral n = 51; Bilateral n = 12 Mean size 2.77 cm (range 0.5–
8.6 cm); TD < 3 cm n = 40;

















Study Patient sex/age No. of tumors Involved lobes Tumor diameter Follow-up
78 year)>60 year n = 29 TD P 3 cm n = 23
Zabaleta (2011); Surgery;
(Retrospective, n = 84); San
Sebastian, Spain
Sex: M/F: 60/24; median age
65.5 year; mean age 65.4 year
1 lesion n = 65; P2 lesions n = 19 N/A TD > 2 cm n = 48; TD < 2 cm n = 36 Median 43 months (range, 0–
130 months)
Pfannschmidt (2003); Surgery;
(Retrospective, n = 167);
Heidelberg, Germany
Sex: M/F: 103/64; mean age
60.2 year (range, 25–81 year)
Median 1 lesion (range, 1–35); 1
lesion n = 84; P2 lesions n = 83
N/A N/A Mean 58.6 ± 42.7 months (range,
0.5–183.9 months)
Higashiyama (2003); Surgery;
(Retrospective, n = 100); Osaka,
Japan
Sex: M/F: 61/39; mean age
60.3 year (range, 39–79 year); <61
n = 49; P61 n = 51
On radiography: 1 lesion n = 49; 2
lesions n = 25; 3 lesions n = 18; 4
lesions n = 4; 5 lesions n = 1; 6
lesions n = 3: Perioperative: 1
lesion n = 55; 2 lesions n = 23; 3
lesions n = 14; 4 lesions n = 3; 5
lesions n = 2; 6 lesions n = 3
Unilateral n = 79; Bilateral n = 21 Max size 0.2–11.0 cm; TD 6 3
n = 59; TD > 3 n = 41
Median 30.3 months (range, 3.6–
168.7 months)
Nakajima (2007); Surgery;
(Retrospective, n = 143); Tokyo,
Japan
Open: sex: M/F: 49/22; age
59.8 year ± 9.9; Thoracoscopy: M/F:
43/29; age 63.3 year ± 11.0
Open 3.4 lesions ± 4.5; scopy 1.6
lesions ± 0.9
N/A Max TD: open 2.7 cm ± 1.8; scopy
1.5 cm ± 0.9
46.7 months ± 54.3 months (open
group); 34.4 months ± 22.0 months
(thoracoscopy group)
Shiono (2004); Surgery; (. . .-
spective, n = 87); Tokyo, Japan
Sex M/F: 57/30; median age 61 year
(range, 23–83 year)
1 lesion n = 66; 2 lesions n = 9; 3
lesions n = 8; 4 lesions n = 3; 5
lesions n = 1
N/A Median size 1.8 cm (range 0.7–
6.7 cm); TD 6 3 cm n = 66;
TD > 3 cm n = 21
Median 32 months (range, 1–
110 months)
Sakamoto (2010); Surgery;
(Retrospective, n = 59); Tokyo,
Japan
Total group: M/F: 162/81, median
age 66 year (range, 9–86 year);
Metastasis group M/F: 81/52,
median age 63 year (range 9–
82 year)
N/A N/A Total group: median size 1.5 cm
(range 0.2–9.5 cm); metastasis
group median size 1.5 cm (range
0.2–7.5 cm); Metastasis group
TD < 3 cm n = 117; TD P 3 cm
n = 16
Median: 37 months (range, 0–
132 months) (for both total group
and metastasis group)
Kanzaki (2011); Surgery;
(Retrospective, n = 156); Osaka,
Japan
Sex: M/F: 91/65; mean age 62 year
(range, 39–83 year)
1 lesion n = 100; 2 lesions n = 32;
P3 lesions n = 24
Unilateral n = 130; Bilateral n = 26 Max TD 6 3 cm n = 115; TD > 3 cm
n = 41
Median 43 months (range, 4–
270 months)
Rolle (2006); Surgery; (. . .-spective,
n = 91); Dresden, Germany
Sex: M/F: 164/164; mean age
61 year (range, 20–80 year)
Total 3267 nodules (average 10/pt);
1 lesion n = 92; P4 lesions n = 161;
P10 lesions n = 69; P20 lesions
n = 30
Unilateral n = 165; Bilateral n = 113 Range of TD 0.3–8 cm N/A
Rolle (2006); Surgery; (. . .-spective,
n = 91); Dresden, Germany
Sex: M/F: 164/164; mean age
61 year (range, 20–80 year)
Total 3267 nodules (average 10/pt);
1 lesion n = 92; P4 lesions n = 161;
P10 lesions n = 69; P20 lesions
n = 30
Unilateral n = 177; Bilateral n = 151 N/A Mean 31 months, median
22.5 months (range, 1–
198 months)
pp = per patient.
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All treatment outcome data are summarized in Table 3.
Local control of treated metastases differed between the stud-
ies. Data on local control were not always provided but if so, these
data were reported in either progression free survival (PFS) or dis-
ease free survival (DFS). Median PFS reported in the RFA studies by
Yan et al.13,14 was 15 months (range, 3–40), while 2-year local PFS
was 56%.14 Data on local control were not provided in other RFA
studies.
Six surgery studies reported local control. Brouquet et al.18 and
Ogata et al.20 provided DFS data for patients treated with both he-
patic and pulmonary metastasectomy, with 5-year DFS being 25%
and 27% respectively. Ogata et al.20 also reported on data on 5-year
lung DFS being 35%.
The 5-year DFS reported by Chen et al.21 and Lin et al.22 were
34.4% and 19.5%, respectively. Rama et al.19, reported a mean DFS
of 52 months ± 6 months and Takakura et al.23 found a DFS of
13 months (range, 2–35 months).
Overall survival
Median Overall Survival (OS) was reported in 11 of 27 articles.









78 R SR 1-year/3-year/5-year: 83.
Yan (2006) 55 R PFS median 15 months (rang
(range, 4–40 months)
Yan (2007) 55 R PFS median 15 months (rang
85%/64%/46%; Median OS 33




112 P DFS 3-year/5-year: 28%/25%
(after liver + lung resection
Koga (2006) 58 R SR 5-year/10-year: 29%/20%




Park (2010) 195 R SR 5-year: 71.2%
Headrick
(2001)
58 R SR 5-year/10-year: 30%/16%
Hornbech
(2011)
53 R Estimated SR 5-year: 50.3%,
61.7%, median 28.6 months (
Inoue (2004) 128 R Estimated SR 5-year: 45.3%
Chen (2009) 84 R DFS 5-year/10-year: 34.4%/3
Hwang (2010) 125 P Median 37 months
Riquet (2010) 117 R SR 5-year/10-year: 41%/27%,
Rama (2008) 62 R DFS mean 52 ± 6 months; SR
Takakura
(2009)
56 R DFS 13 months (range, 2–35
Lin (2009) 63 P DFS 5-year: 19.5%; SR 5-year
Zabaleta
(2011)
84 R SR 3-year/5-year: 70.2%/54.3
Pfannschmidt
(2003)
167 R Cumul. SR 5-year: 32.4%, me
Higashiyama
(2003)
100 R SR 3-year/5-year: 62.2%/49.4
Nakajima
(2007)
143 R SR 5-year: 49.3% (open resec
Shiono (2004) 87 R SR 5-year: 61.4%
Sakamoto
(2010)
59 R SR 5-year: 69.9% (CRC patien
Kanzaki
(2011)
156 R SR 3-year/5-year/10-year: 71
Rolle (2006) 91 R SR 5-year: 41% (complete re
Rolle (2006) 91 R SR: 1-year/3-year/5-year: 81
(incomplete resection)The two articles by Yan et al.13,14 reported from the one dataset
of 55 patients and provided a median OS of 33 months (range, 4–
40 months). The fourth study concerning RFA by Chua et al.15 re-
ported a median OS of 51 months (95% CI, 19–83 months) for the
total study population of 148 patients with pulmonary metastases
from several primary tumors. Outcome data for the colorectal can-
cer patient subgroup were not available.
Regarding surgery, in the study of Brouquet et al.18, the median
OS was 58 months for patients with both liver and lung metastasec-
tomy. Retrospective studies by Koga et al.24 and Hornbech et al.25 re-
ported median OS of 27 months and 33.5 months, respectively.
Hornbech et al.25 also analyzed the median survival of subgroups
with (15.4 months) or without (28.6 months) concurrent hepatic
metastases. Hwang et al.26 conducted a prospective study with a
median OS of 37 months whereas the retrospective studies by Zabal-
eta et al.27 and Pfannschmidt et al.17 reported median OS of
72 months (range, 0–129 months) and 40.2 months, respectively.
One study (Rama et al.19) reported only a mean OS of
67 months ± 16 months.
Survival rates
Good comparison between survival rates was difficult since
these outcome data were differently reported between the papers.9%/56.1%/34.9%; Median Survival 38.0 months
e, 3–40 months); SR 1-year/2-year/3-year: 85%/64%/46%; Median OS 33 months
e, 3–40 months); Local PFS 1-year/2-year: 74%/56%; SR 1-year/2-year/3-year:
months (range, 4–40 months)
CI, 9–14 months); SR 3-year/5-year: 60%/45%; median OS 51 months (95% CI, 19–
(both liver and lung metastasis) SR 3-year/5-year: 71%/50%; median 58 months
median survival time 27 months
DFS 5-year cumul. 35%; Cumul. SR 5-year 32% (after first resection)
ar: 96.6%/84.5%/70.5%/48.9%
median 33.5 months (total group); 0%, median 15.4 months (also hepatic M+);
no-hepatic M+)
0.6%; SR 5-year/10-year: 60.5%/48.4%
median 45 months
3-year/5-year/10-year: 61%/48%/11%, mean 67 ± 16 months
months); cumul. SR 3-year/5-year 64.9%/48.2%
/10-year: 43.9%/19.5%
%, median 72 months (range, 0–129 months)
dian 40.2 months
%
tion group), 39.5% (thoracoscopy group)
ts)
.4%/56.2%/44%
section); 7% (incomplete resection)
%/53%/35% (all 328 patients) 85%/59%/41% (complete resection) 60%/23%/7%
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ble 3. For analysis 2- and 5-year survival rates were chosen, since
these were the two most reported survival data. In papers which
did not provide either of these, but did have a Kaplan–Meier curve,
2- and 5-year survival rates were extracted manually from this
curve.
For RFA 2-year survival rate (SR) ranged from 64–73%12–15 and
5-year SR from 34.9–45%.12,15 The surgical series provided 2-year
SR range from 64–88%.17–25,28–32 The 5-year SR reported for sur-
gery ranged from 29–71.2%.17–25,27–35 As seen in various uni- and
multivariate analyses12–14,35, survival outcomes are influenced by
the size of the intrapulmonary lesion, especially in patients treated
with RFA. Tumors larger than 3 cm give significantly shorter long-
term survival and local control rates than lesions smaller than
3 cm.
Mean and median tumor size were difficult to compare be-
tween surgery and RFA studies, due to differences in reporting,
but seemed similar for both therapies (Table 2).Complications
In only 20 articles treatment-related mortality and/or morbidity
were described, which are tabulated (Table 4). The remaining 7
studies were not included in this table.
Treatment-related mortality rates were reported by three of the
studies investigating RFA.13–15 Mortality rate was 0% in all three,
but was defined differently (Table 4). Morbidity and complication
rates differed but all four RFA studies reported pneumothorax as
the most common post-treatment complication (22% of sessions12,









N/A N/A Pneumothorax in 31/140 sessions (22.1%)
in 2 sessions (1.4%); Minor complication
Yan (2006) 0% 42% Post-RFA: pneumothorax (16), fever (6), p
pneumothorax, 1 for pleural effusion. Du
Yan (2007) 0% 42% Intrapulmonary bleeding (5); pneumotho
Chua (2010) 0% N/A Morbidity: pneumothorax (66), pleural ef
placement (45) of which one ptn develop
Brouquet
(2011)
0% 4% For lung resection only: Mortality 0% (Tre
Koga (2006) 0% N/A N/A
Ogata (2005) 0% 1% Hemorrhage n = 1
Park (2010) 0% N/A N/A
Headrick
(2001)
0% 12% Ileus (2), bile leak (1), chyle leak (1), inci
Hwang (2010) 0% N/A N/A
Riquet (2010) 0% 14.5% Atrial fibrillation (2); persistent air leaks
nerve palsy (1); miscellaneous (2)





8.3% Persistent air leaks (3); nosocomial pneu





N/A Postoperative deaths by septic multiorga
Nakajima
(2007)
1.4% N/A Postoperative deaths (pulmonary thromb
Shiono (2004) 0% N/A N/A
Sakamoto
(2010)
0% 9.8% Persistent air leak (3); pneumonia (2); cer




Rolle (2006) 0% N/A Major morbidity: persistent air leaks (2);
Rolle (2006) 0% N/A Major morbidity: persistent air leaks (2);
Perioperative; In-hospital; Treatment-related; Operative; Postoperative; 30-day.
Including hepatic surgery complications.
Metastasis group.Three surgical studies reported treatment-related mortalities
(Zabaleta et al.27, Pfannschmidt et al.17, Nakajima et al.36) of 2.4%,
1.8% and 1.4%, respectively. All other fourteen studies which re-
ported complications showed mortality rates of 0%.13–15,18–
20,24,26,28,31–35,37,38
Morbidity rates ranged from 0–14.5%, with large variations in
the reporting of complications. Some studies for example reported
only major morbidity (e.g. Kanzaki et al.32) whereas others re-
ported all complications that occurred.Discussion
Since the proposal of the existence of oligo-metastases by Hell-
mann et al.,3 local therapies have been used for treating these few
distant metastases with curative intent. For oligo-metastases in the
lung, the most commonly used local treatment modalities are sur-
gery, RFA and SBRT, see Fig. 2. To our knowledge the present study
was the first to systematically review and try to compare metasta-
sectomy, RFA and SBRT for patients with pulmonary metastases of
colorectal cancer with regard to local tumor control, OS and
complications.
By systematically searching databases, we identified 27 pub-
lished studies, of which four were dealing with RFA and 23 with
surgery.12–38 No eligible studies were found on SBRT, even after
adjusting the selection criteria to a minimum of 25 patients and
a minimal follow-up of 12 months. For this reason, no analysis
was made on SBRT data. Of the included four RFA series, three
studies were from the same institute, which has to be kept in mind
given the possibility that some patient data may be used in multi-
ple studies and therefore may bias outcome data. In two surgical, chest tube placement in 18 sessions; aseptic pleuritis with chest tube placement
13/140 (9.3%); Major complication 20/140 (14.3%)
leural effusion (4), pleuritic chest pain (2); chest drain n = 10, nine for
ration of chest drain 2 ± 2 days
rax (16); pleural effusion (4); persistent pleuritic chest pain more than 1 week (2)
fusion (16), consolidation (10), bleeding (1), pleuritic chest pain (12); chest tube
ed severe consolidation and lung abcess with empyema
atment-related); Morbidity 4% (n = 4) (postoperative)
sional hernia (1), postoperative bleeding (1), pulmonary embolus (1)
(6); atelectasis (1); empyema (2); hemorrhage (2); pneumonia (1); recurrent
sufficiency (1), hemorrhage (1); wound infection (1)
omonia (1); partial intestinal obstruction (1); atelectasis (1) requiring
ing reintervention)
n failure after pneumonia (2); death by sudden cardiac failure (1)
oembolism; gastrointestinal bleeding) (2)
ebral infarction, postoperative bleeding, atelectasis, duodenal ulcer, chylothorax,
each)
intrapleural bleeding (2); late pneumothorax (2)
intrapleural bleeding (2); late pneumothorax (2)
Fig. 2. Leuven–Maastricht guideline map for the local treatment of lung metastases.
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to use these data only once in our analysis.
In the identified papers, outcome data were reported in various
ways, with different parameters mentioned or sometimes incom-
plete data. This resulted in difficulties analyzing and comparing
these outcomes. Also, diagnostic differences may have influenced
outcome, such as differences in CT slice thickness. This is not al-
ways reported clearly but could influence outcome results. Survival
outcomes used for analysis are either reported in the papers or ex-
tracted manually from Kaplan–Meier curves and weighted for
number of patients afterwards. Since there is a strong heterogene-
ity in the reporting of outcome data, the quality op comparisons
between surgery and RFA are difficult en should be approached
with care. Comparing RFA and surgery, the differences in OS are
small and in the absence of randomized trial, no firm conclusions
can be drawn. Since tumors larger than 3 cm give significantly
shorter long-term survival and local control rates than lesions
smaller than 3 cm, differences in tumor size in the included pa-
tients in the RFA and surgery studies may have influenced the
results.
Investigating complication rates, RFA seems to have better out-
comes, since the mortality rate in 3 studies was 0%, compared to
mortality rates of 1.4–2.4%, reported in three surgical stud-
ies.17,27,32 However, morbidity rates are higher in the RFA studies
compared with the surgery papers, with an average of 45.5% for
the three studies12–15 compared with 6.6% in nine surgical stud-
ies18–20,27,28,32,34,35,37 (Table 4). The problem however, is that prob-
ably not all complications are reported, mainly in these surgery
articles, in which sometimes only major complications are
reported.Because of the wide variety in data, caused by patient selection
and the lack of phase III trials, no conclusions can be drawn on
effectiveness of surgery for lung metastases of colorectal cancer
in comparison to RFA.
This review points out that there is a need for prospective, ran-
domized studies, including studies that investigate the effective-
ness and long-term survival of SBRT and RFA. It is to our opinion
very likely that SBRT represents an effective treatment method in
this population. Based on outcomes from studies investigating
SBRT for primary lung cancer, e.g. Timmerman et al.39, Senan et al.40
and a review by Fernando et al.9 in which SBRT and RFA seemed to
be effective and useful treatment modalities for high-risk primary
lung cancer patients, we assume that outcomes for pulmonary
metastases may be comparable to those for primary lung cancer.
This assumption is confirmed by the prospective, multicentre
study of Lencioni et al.41 in which both NSCLC and pulmonary
metastasized colorectal cancer patients were treated with RFA.
This paper was not included in this review because of a follow-
up of only 15 months. However, results show that there is no
difference in response between these two patient-groups. Overall
survival at 1 and 2 years were 70% and 48% respectively for NSCLC
and 89% and 66% for patients with colorectal metastases.Conclusions
Because of the lack of randomized trials, no firm conclusions
can be drawn about the relative merits of surgery, RFA and SBRT
for colorectal lung metastases. However, only surgical series
provide large prospective series with large patient numbers.
R.C.J. Schlijper et al. / Cancer Treatment Reviews 40 (2014) 60–67 67Therefore, surgery is the treatment of choice in this condition.
Other therapy options such as RFA and SBRT have been reported
to be successful as well, but most series are at present too small,
retrospective and or have a follow-up that is too short to draw
definitive conclusions. Nevertheless, retrospective RFA studies
support its effectiveness and this modality may thus be regarded
as a less defined alternative for surgery. Finally, because of our
stringent a priori inclusion criteria for published series, we could
not include radiotherapy studies in this review. Indeed, published
studies of SBRT for colo-rectal metastases have still a short follow-
up, which is not surprising in view of the relative new technology
that SBRT is and its only recent wide-spread use. Assuming an
analogous efficacy for colo-rectal metastases as for primary NSCLC,
SBRT series when more maturated may well establish radiotherapy
as the third local treatment option for patients with colo-rectal
lung metastases. Ideally, randomised trials should be performed
to define the value of all three modalities, taking into account pa-
tient and disease characteristics.Conflict of interest
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